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a blinded analysis. The images were analyzed by image analysis software. The density and
area of the pixels was proportionate to the amount of the clot formed on the graft surface.
Results: The pressure gradient between the groups was identical throughout the study,
meaning similar flow characteristics were maintained in all branches. The pretreated grafts
had fewer blood clots adhered to the surface by direct visual inspection. The image analysis
showed 5 vs.39 clots, 0.01% vs. 1.8% clotted area and 62 vs. 5630 clot pixel area between
the treated and non-treated grafts respectively, p 0.05.
Conclusion: Pretreatment of the synthetic graft with heparin prior to implantation
reduces the risk of early clot formation. This simple practice might be helpful to prevent
initial thrombosis of the graft and later occlusion especially in critical situations where the
patency of the graft is crucial.
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A Novel Nano Particle Sirolimus Delivery Via Coated Balloon
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Frank Kolodgie,2 Renu Virmani,2
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Objectives: Objective of this study was to develop non-polymeric sirolimus nanoparticle
coated balloon and demonstrate in-tissue transfer through DCB in rabbit model.
Background: Drug coated balloon (DCB) is an emerging technology. To date paclitaxel
is a choice in DCB. Due to lipophilic properties of sirolimus, short time delivery through
DCB is a major challenge. To overcome current limitations, we hypothesized; nanopar-
ticle sirolimus coated on the balloon can provide better delivery and retention.
Methods: We prepared phospholipid encapsulated sirolimus and coated on the balloon
with novel coating formulation. The characteristics of the nanoparticle sirolimus DCB
was tested in both an in-vitro and preclinical in-vivo models. New Zealand rabbits
underwent drug coated balloon dilatation in iliac arteries for pharmacokinetics, confocal
microscopy and scanning electronic microscopy studies.
Results: Sirolimus nanoparticles were	400nm with stable solution. Coating surface was
smooth without defect and irregularities. In-tissue uptake of sirolimus was at 1, 7 and 14
days with concentration of 140.6, 15.5 and 5.5 ng/mg, respectively. Sirolimus coated
balloon with 3x inflations was also safe in the rabbit iliac arteries. Confocal microscopy
showed homogeneous fluorescent tagged nano sirolimus (DTF-nSRL) distribution into
the artery wall with intima to adventitia flow. None of the in-vivo investigation has
reflected emboli in downward stream.
Conclusion: Present set of experiments showed adequate amount of sirolimus was
delivered through non-polymeric DCB. Multiple inflation demonstrated safety to
co-relate with actual clinical outcome. Confocal imaging has showed homogenous
distribution in cross section and longitude parts. Path of drug travel was to the deepen area
of arterial wall upon time from intima to adventitia (Table 1).
Table 1. Depth of DTF-nSRL signal punctuation in rabbit iliac arteries
Time Point 24 hour 3 day 7 day
Depth of penetration 10-20m 10-30m 10-40m
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Comparative In Vitro Effects Of Paclitaxel, Everolimus, And Tacrolimus On
Macrophage-derived Foam Cells, Smooth Muscle Cells, And Endothelial Cells
Steven Hsu, Eugen Koren, Yen Chan, Mirna Koscec, Debby Feder
Abbott Vascular, Santa Clara, CA
Background: Macrophage-derived foam cells (FC) play a key role in atherosclerotic
lesion progression. Effects of different drugs used in drug-eluting stents (DES) on FC
behavior have not been well characterized. We used an in vitro model to compare effects
of paclitaxel, everolimus, and tacrolimus on FC, human coronary endothelial cell
(HCAEC), and human coronary smooth muscle cell (HCASMC) viability, FC gene
expression, and FC inflammatory cytokine levels.
Methods: FC were derived from human THP1 macrophages with acetylated LDL,
followed by treatment with paclitaxel, everolimus, or tacrolimus (10-5-10-11M) for 24 hrs
(n4). HCAEC and HCASMC were similarly treated with all three drugs. Cell lysates
and media supernatants were analyzed for apoptosis/necrosis using a Cell Death
Detection ELISAPLUS (Roche, Pleasanton, CA) assay. FC lysates were also evaluated
for apoptosis (survivin, clusterin) and autophagy (MAP1LC3) gene expression via a
Quantigene® Plex assay (Affymetrix, Santa Clara, CA). FC supernatants were analyzed
for MCP1 levels via a Procarta® mmunoassay (Affymetrix). Statistical significance was set
at p0.05 by ANOVA/Holm’s t-test.
Results: FC apoptosis was significantly increased compared to control at 10-5M for both
everolimus and paclitaxel, with no effects on FC necrosis for both drugs. Tacrolimus did
not affect FC apoptosis or necrosis. Paclitaxel (10-5M) significantly increased clusterin and
decreased survivin expression in FC. Tacrolimus did not affect gene expression while
everolimus (10-5M) significantly increased MAP1LC3 and clusterin (p0.10) and
decreased survivin expression in FC. Everolimus (10-5M) significantly decreased MCP1
in FC supernatants. Effects of all three drugs on HCASMC and HCAEC viability were
also explored. While everolimus and tacrolimus did not affect apoptosis or necrosis,
paclitaxel (10-5M) significantly increased HCASMC and HCAEC apoptosis and
necrosis.
Conclusion: The three drugs explored in this study have variable effects on FC,
HCASMC, and HCAEC. Unlike paclitaxel and tacrolimus, everolimus may inhibit FC
accumulation in atheromas through selective autophagy/apoptosis of FC and inhibition of
monocyte recruitment into the arterial wall.
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Do Second-Generation Drug-Eluting Stents Outperform First-Generation Drug-Eluting
Stents When Used in “Full Metal Jacket” Percutaneous Coronary Intervention
Procedures?
Joshua P Loh, Lakshmana K Pendyala, Hironori Kitabata, Salem M Badr,
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Background: Diffuse coronary lesions are often treated with long and overlapping
drug-eluting stents (DES) creating a full metal jacket, however the impact on clinical
outcomes comparing different generation DES has not been described.
Methods: We conducted a retrospective analysis of 98 patients with full metal jacket
stenting, defined as the total and continuous stent length of  50 mm in a single vessel,
treated using either first-generation (sirolimus- and paclitaxel-eluting) DES or second-
generation (everolimus-eluting) DES.
Results: Full metal jacket stenting was performed in 36 patients/71 lesions with
second-generation DES (Xience V or Promus); and 62 patients/151 lesions with
first-generation DES (Cypher or Taxus). Baseline characteristics were similar between the
groups. More second-generation DES were used per patient than first-generation DES
(3.2 vs. 2.6, p0.001); mean stent length (23.9 vs. 25.3mm) and diameter (2.9mm in
both) were similar (pNS). Angiographic success was 100% in both groups. At 1-year
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follow-up, a reduction in major adverse cardiac events (MACE) was observed with
second-generation compared to first-generation DES (5.6 vs. 16.1%, p0.20), driven by
a four-fold decrease in target vessel revascularization (2.9 vs. 14.8%, p0.09), although
not reaching statistical significance. Only 1 patient (1.6%) in the first-generation DES and
none in the second-generation DES had definite stent thrombosis (Table).
Conclusion: In this study of full metal jacket stenting for diffuse lesions, second-
generation DES compared to first-generation DES demonstrated a favorable trend
toward reduction in repeat revascularization and MACE at 1-year with acceptable safety
profile.
Clinical outcomes at 1-year between first and second generation DES
Second-
generation
DES (n36)
First-
generation
DES (n62) P value
Major adverse cardiac events 2 (5.6%) 10 (16.1%) 0.20
Death 1 (2.8%) 1 (1.6%) 1.00
Q-wave myocardial infarction 0 0 -
Target vessel revascularization 1 (2.9%) 9 (14.8%) 0.09
Target lesion revascularization 1 (2.9%) 7 (11.5%) 0.25
Deﬁnite stent thrombosis 0 1 (1.6%) 1.00
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Three Years Follow Up Data Demonstrate Safe And Effective Treatment Of De Novo
Calcified Coronary Lesions By Orbital Atherectomy System
Keyur Parikh, Roosha Parikh, Apurva Patel, Milan Chag
Care Institute of Medical Sciences, Ahmedabad, India
Background: Coronary Artery Disease continues to be a widespread and growing
problem worldwide. Performing PCI on calcified lesions can lead to higher MACE rates
and stent under expansion/malapposition. The Orbit I trial was conducted to evaluate the
safety and performance of the Diamondback 360 Orbital Atherectomy System (OAS)
(Cardiovascular Systems, Inc., St. Paul, MN, USA) for the treatment of calcified coronary
lesions.
Methods: From May 2008 to July 2008, 33 patients were enrolled in ORBIT I study
based on several criteria, including a de novo, coronary lesion with stenosis 50% and
100% and at least one quadrant of calcification via IVUS. The patients were treated with
OAS prior to stent placement. The patients were followed for 36 months at Care Institute
of Medical Sciences, Ahmedabad, India to evaluate the MACE rate.
Results: Of the 33 patients, 90.90% (n30/33) were males with an average age of 54.9
years. The ACC/AHA lesion class was: Type A 6.06% (n2/33); Type B1 33.33%
(n11/33); Type B2 60.60% (n20/33). The % diameter stenosis was 85.75%; lesion
length was 15.90 mm. The procedural success was 97% (32/33) with one case where
IVUS/device was not able to cross the lesion due to severe calcification. All stents were
successfully deployed with 0.3% 1.8% residual stenosis. The observed MACE rate was
as follows: in-hospital 6.06% (n2/33); 30 days 9.09% (n3/33); 6 months 12.12%
(n4/33); 24 months 15.15% (n5/33); and 36 months 18.18% (n6/33). MACE rate
comprised of 2 patients with a non Q-wave MI in-hospital; one patient with non Q-wave
MI at 30 days that led to TLR; and one patient with cardiac death at 6 months, 24
months and 36 months, respectively.
Conclusion: This case series demonstrates that OAS safely and effectively modified
calcified lesions and facilitated stent delivery in this difficult-to-treat plaque morphology,
which continues up to three years post index procedure.
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Hyperinvasive Approach To Out-of Hospital Cardiac Arrest Using Mechanical Chest
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Background: Out of hospital cardiac arrest (OHCA) has a poor outcome. Recent
non-randomized studies of ECLS (extracorporeal life support) in OHCA suggested
further studies to define population that would benefit from ECLS. Ongoing prospective
randomized study compares prehospital intraarrest hypothermia combined with mechan-
ical chest compressions, intrahospital ECLS and early invasive assessment in refractory
OHCA of presumed cardiac origin compared to a standard of care. This abstract describes
methodology of the trial and results of presimulation and simulation phase.
Methods: Patients with witnessed OHCA without ROSC (return of spontaneous
circulation) after a minimum of 5 minutes of ACLS (advanced cardiac life support) by
emergency medical service (EMS) team are randomized to standard vs. hyperinvasive arm.
In hyperinvasive arm, mechanical compression device together with intranasal evaporative
cooling is instituted and patients are transferred directly to cardiac center under ongoing
cardiopulmonary resuscitation. After admission, ECLS inclusion/exclusion criteria are
evaluated and if achieved, veno-arterial ECLS is started. Invasive investigation and
standard postresuscitation care follows immediately. Patients in standard arm are managed
on scene. When ROSC is achieved, patients are transferred to cardiac center and further
treated as per recent guidelines. During the presimulation phase mechanical chest
compression device has been used routinely in all patients with OHCA, during the
simulation phase patients were to practice the logistics of the study.
Results: Since January until October 2012 we enrolled 40 patients, 32 to presimulation
and 8 to simulation protocol. Average age was 61 years (21-87), 85% were men. Acute
coronary syndrome was the cause in 21 (53%) patients, STEMI 17 (43%), cardiac origin
of OHCA was identified in 63% of patients. Average time until ROSC was 40 minutes,
median 32 minutes (15-120). Twenty (50%) patients survived, CPC (Cerebral
Performance Category) 12 during hospitalization reached 15 of 20 survivors
(75%) and 1 of 20 nonsurvivors (5%). Survival in patients admitted under ongoing
CPR was 5 of 17 (30%).
Discussion: A combined, hyperinvasive approach to refractory OHCA is a viable option
with challenging preliminary results. The protocol is opened for sharing by other cardiac
centers with available ECLS and cathlab teams trained to admit patients with refractory
cardiac arrest under ongoing CPR. Supported by IGA NT 13225-4/2012, registered
under ClinicalTrials.gov NCT01511666.
Other
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Renal Artery Denervation in Chronic Kidney Disease Patients
Amitabh Yaduvanshi, Mohan Nair
Maxhealthcare, New Delhi, India
Renal Denervation Therapy (RDN) have been proven to be useful in resistant hyperten-
sion patients. The Symplicity Trials did not include patients with renal disease whereas,
a significant number of end stage renal disease (ESRD) patients who have resistant
hypertension despite being on multiple drugs and the benefits of RDN in such patients
have not been reported.
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